Antibodies and antibody derived proteins for chronic liver diseases, immune mediated inflammatory disease, & cancer

Baliopharm AG is a biotechnology company dedicated to developing innovative antibody therapeutics with enhanced safety profiles for various diseases, including chronic liver diseases, immune-mediated inflammatory diseases, and cancer. The company focuses on monoclonal antibodies and antibody-derived proteins, such as monovalent formats and bispecific antibodies, which exhibit unique target selectivity. Their drug candidates, including Atrosab and Atrosimab, specifically target the pro-inflammatory tumor necrosis factor receptor 1 (TNF-R1), effectively blocking its activation by TNF-alpha. This targeted approach not only mitigates inflammatory responses but also reduces the risk of severe side effects commonly associated with other TNF antagonists.

Baliopharm's product pipeline includes promising candidates for treating autoimmune diseases and chronic liver conditions. Their bispecific antibody, Novotarg, is designed to selectively target activated B-cells expressing both CD20 and CD95, allowing for the targeted elimination of malignant B-lymphocytes while sparing healthy cells. Additionally, the company is exploring the therapeutic potential of their antibodies in chronic liver diseases, particularly Nonalcoholic Steatohepatitis (NASH), where preclinical studies have shown promising efficacy. Through these advanced therapeutic strategies, Baliopharm aims to revolutionize treatment options for complex diseases while minimizing adverse effects.

Switzerland

Baliopharm was acquired by Promethera Biosciences on April 10, 2018.

Baliopharm was founded in 2006 as Celonic AG, a service company for the contract development and manufacturing of biopharmaceutical compounds, based on the...

Baliopharm

Company Details